Indication
AML Arising From Antecedent Hematologic Disorder (AHD)
1 clinical trial
2 products
5 drugs
Clinical trial
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 MutationStatus: Active (not recruiting), Estimated PCD: 2018-12-13
Product
AG-120Product
AG-221Drug
cytarabineDrug
daunorubicinDrug
idarubicinDrug
mitoxantroneDrug
etoposide